Method for constructing miniature pig tumor model by inductively expressing K-Ras gene

Through the combination of tetracycline-induced expression system and transposon technology, a small pig tumor model of induced expression of K-Ras gene was constructed, solving the problems of long cycle, low efficiency and insignificant phenotype in the existing technology, and achieving high efficiency and ability The construction of tumor model of control has important biomedical research value.

CN118956960AInactive Publication Date: 2024-11-15YUNNAN AGRICULTURAL UNIVERSITY
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202411426219.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-14
Publication Date
2024-11-15
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The prior art has long cycles, low efficiency, unobvious phenotype, unstable genetics, poor controllability of gene expression when constructing animal tumor models, making it difficult to meet the rapidly developing biomedical research needs.

Method used

Using tetracycline-induced expression system and transposon technology, HA-krasG12DcDNA was synthesized in vitro by constructing Tet-On transposon expression vectors, and co-transfected into pig fetal fibroblast cell lines by electroporation for gene editing, followed by Somatic nuclear transplantation and cloning, using tetracycline to promote tumorigenesis, and construct a small pig tumor model for induced expression of K-Ras gene.

Benefits of technology

A K-Ras gene-induced minipig tumor model with short cycle, high efficiency, obvious phenotype and controllable gene expression has been achieved. The cloning success rate and survival rate have been improved. It is suitable for human tumor biology research and promotes the rapidity of the biomedical industry. develop.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118956960A_ABST
    Figure CN118956960A_ABST
Patent Text Reader

Abstract

The invention relates to a method for constructing a miniature pig tumor model by inductively expressing a K-Ras gene, which is characterized in that a Tet-On transposon expression vector PB-CAG-Teton3g-T2A-mcherry-TRE3GS-MCS-Puro is constructed by combining a Tet-On inducible expression system with a transposon technology. The method comprises the following steps: obtaining a K-Ras gene editing positive cell line, constructing a K-Ras gene editing cloning embryo, transplanting the embryo into a fallopian tube of a pregnant sow, producing a K-Ras gene editing cloning pig individual, inducing K-Ras expression by feeding tetracycline, promoting generation of cloned pig tumors, and obtaining the miniature pig tumor model. The technical problems that an existing model is long in construction period, low in efficiency, not obvious in phenotype, poor in gene expression controllability and the like are solved, batch production of the K-Ras gene induced expression miniature pig tumor model is achieved, and the method has important application value and prospects in the field of tumor biology research.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of animal biotechnology, and specifically relates to a method for constructing a miniature pig tumor model by inducing K-Ras gene. Background Art

[0002] As the incidence and mortality of tumors have increased year by year, tumor diseases have evolved into a major life science issue in my country's public health field, and animal tumor models have become one of the hot topics in the current field of tumor biology research. At present, there are few reports on animal tumor models. Some studies have reported that the K-Ras and TP53 genes in the bone marrow mesenchymal stem cells of pigs were mutated through the Cre-Loxp system, and then the bone marrow mesenchymal stem cells edited by the gene were transplanted to obtain a pig osteosarcoma model.

[0003] Although the Cre-loxp system is very mature in theory, it still has shortcomings and limitations in practical applications. Gene knockout mediated by the Cre-Loxp system relies on homologous recombination to integrate DNA fragments into the cell genome, and the probability of non-homologous recombination in cells is much greater than the probability of homologous recombination, so a lot of time and effort are required to screen out cells with homologous recombination, resulting in low efficiency. In the production of gene-edited pigs, in order to ensure a uniform genotype, the SCNT method is usually used for construction. However, due to the low efficiency of homologous recombination, multiple knock-ins require multiple rounds of gene editing and cloning, resulting in a long cycle for obtaining gene-edited animals.

[0004] Therefore, there is an urgent need for a method to construct a tumor model with a short cycle and obvious phenotypic characteristics. This will be better applied to research in the field of human tumor biology and will be of great significance in promoting the rapid development of the biomedical industry. Summary of the invention

[0005] In view of the above technical problems and practical needs, the present invention provides a method for constructing a K-Ras gene inducible expression miniature pig tumor model. The method combines the tetracycline inducible expression system with the transposon technology to construct the Tet-On transposon expression vector PB-CAG-Teton3g-T2A-mcherry-TRE3GS-MCS-Puro. G12D cDNA sequence and HA-kras G12D The cDNA sequence was cloned into the MCS position of the Tet-On transposon expression vector to obtain PB-TMP-HA-kras G12D Expression vector. G12DThe K-Ras gene was co-transfected with the transposase into the porcine fetal fibroblast cell line through electroporation, and the K-Ras gene-edited positive cell line was obtained through screening. The K-Ras gene-edited cloned embryo was constructed by somatic cell nuclear transplantation as the donor cell, and then transplanted into the oviduct of the estrus surrogate sow to produce the K-Ras gene-inducible expression cloned pig individuals, and the genotype and expression were identified. K-Ras expression was induced by feeding an appropriate amount of tetracycline to promote the occurrence of cloned pig tumors, and a miniature pig tumor model was obtained through multi-omics technology identification such as phenotypic omics. This method can overcome the technical problems of the existing model construction cycle, low efficiency, unclear phenotype, genetic instability, and poor controllability of gene expression to a certain extent. Further, the batch construction of the K-Ras gene-inducible expression miniature pig model can be realized through continuous cloning technology, which has important application value in the field of tumor biology research.

[0006] The present application provides a method for constructing a K-Ras gene inducible expression miniature pig tumor model, the method comprising: (1) The transposon-induced expression plasmid was transformed into DH5α competent bacteria by PCR for amplification, and the PB-TMP-MCS target plasmid was screened; The transposon-inducible expression plasmid includes flanking PiggyBac inverted terminal repeat sequences, three promoters, and corresponding polyA sequences; (2) The PB-TMP-MCS target plasmid obtained in (1) was cut with restriction endonucleases, and the in vitro synthesized HA-kras series was cloned into the MCS position. After verification by sequencing, it was named PB-TMP-HA-kras. G12D ; The nucleotide sequence of HA-kras is shown in SEQ.ID.NO:1; PB-TMP-HA-kras G12D The nucleotide sequence is shown in SEQ.ID.NO:2; (3) PB-TMP-HA-kras obtained in (2) G12D Co-transfected with transposase into porcine fetal fibroblast cell line by electroporation, and K-Ras gene editing-positive porcine fetal fibroblast cell line was obtained by single cell clone screening; (4) The K-Ras gene-edited positive porcine fetal fibroblast cell line obtained in (3) was used as a donor cell for somatic cell nuclear transplantation to construct K-Ras gene-inducible expression cloned embryos, which were then transplanted into the oviduct of a surrogate sow and given birth to obtain K-Ras gene-inducible expression cloned pigs.

[0007] Furthermore, the three promoters in (1) are TRE3GS, CAG and PGK; the TRE3GS is derived from the PLVX-TetOn-Puro plasmid; the CAG is derived from the PX458 plasmid; and the PGK is derived from the PGLE-U6-mCherry plasmid.

[0008] Furthermore, the restriction endonuclease in (2) is EcoRI enzyme.

[0009] Furthermore, the transfection method in (3) is: liposome transfection and / or electroporation transfection; the donor cell in (4) is a K-Ras gene-edited single cell clone or cloned fetal fibroblast or cloned pig ear tissue fibroblast.

[0010] Furthermore, the transfection is electroporation transfection.

[0011] Furthermore, the method further comprises the following steps: (5) Identification of the K-Ras gene-inducible expression cloned pigs described in (4); identification includes histological, immunohistochemical, and omics analysis of the phenotypes and organs of the K-Ras gene-inducible expression cloned pigs.

[0012] Furthermore, the method further comprises the following steps: (6) The K-Ras gene-inducible expression cloned pigs obtained in (4) were fed tetracycline to maintain the stability of the model. The amount of tetracycline fed was 30 mg / kg, once every 3 days.

[0013] Beneficial effects of the present invention: 1. The K-Ras gene-inducible expression miniature pig tumor model provided in this application uses miniature pigs as the species for the disease model. This is because miniature pigs are more similar to humans in terms of genome homology, body size, physiology and biochemistry, tissue anatomy, and immune metabolism, and can better mimic the occurrence of tumors in the human body.

[0014] 2. The K-Ras gene-inducible expression miniature pig tumor model provided in this application, in the process of constructing an animal model through gene editing technology, compared with previous gene editing technologies such as homologous recombination, ZFNs, TALENs, CRISPR / Cas9, etc., introduces the Tet-On system. The gene-edited miniature pig tumor model constructed by combining somatic cell nuclear transfer technology can more accurately simulate the occurrence and development of tumors and the genetic and biological characteristics, effectively shortening the model preparation cycle and improving the model construction efficiency.

[0015] 3. The present application provides a method for constructing a miniature pig tumor model with inducible expression of the K-Ras gene. During the feeding process of the miniature pig tumor model with inducible expression of the K-Ras gene, adding an appropriate amount of tetracycline to the feed can achieve the inducible expression regulation of the K-Ras gene in the miniature pigs, which is beneficial to increasing the incidence of tumors and has important significance and value for in-depth research on tumor biology. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] Figure 1 For exogenous kras G12D Schematic diagram of gene editing strategy; Figure 2 Schematic diagram of the principle of Tet-On inducible expression; Figure 3 PB-TMP-HA-kras G12D Schematic diagram of the vector; (A) PB-TMP-HA-kras G12D Vector diagram; (B) PB-TMP-HA-kras G12D Sequencing comparison results of the vector; Figure 4 This is the result of the activity verification of the Tet-On vector; (A) Expression of fluorescent proteins in cells after 24 hours of Dox induction; (B) Flow cytometry detection results of red fluorescent protein (mCherry) and green fluorescent protein (zsGreen). "+" indicates Dox induction, and "-" indicates no Dox induction.

[0017] Figure 5 for kras G12D Protein expression level; Dox induces cell HA-kras G12D Protein expression level, β-acting was used as the internal reference gene, “+” indicates Dox-induced treatment, and “-” indicates no Dox-induced treatment, and the Dox concentration was 2 μg / mL.

[0018] Figure 6 for kras G12D Downstream signaling pathway ERK1 / 2 protein expression level Dox induces cell HA-kras G12D The expression levels of downstream related proteins pERK1 / 2 and ERK1 / 2, β-acting as the internal reference gene, "+" indicates Dox-induced treatment, "-" indicates no Dox-induced treatment, and the Dox concentration is 2 μg / mL.

[0019] Figure 7 It is the result of fetal and genotype identification of K-Ras gene inducible expression; A is for kras G12D Inducible expression of fetus; B is the result of fetal PCR identification; C is the result of fetal kras G12D Gene sequence Sanger sequencing results.

[0020] Figure 8 The results of K-Ras gene inducible expression cloned piglets and genotype identification; A is for kras G12D Inducible expression cloned pig; B is the result of PCR identification of cloned pig; C is the result of kras G12D Gene sequence Sanger sequencing results. DETAILED DESCRIPTION

[0021] In order to make the objectives, technical solutions and beneficial effects of the present invention clearer, the preferred embodiments of the present invention will be described in detail below to facilitate understanding by technicians.

[0022] The use of emerging gene editing technologies such as CRISPR / Cas9 and transposon-induced expression combined with somatic cell cloning technology to establish a K-Ras gene-inducible expression miniature pig tumor model will be better applied to research in related fields of human tumor biology and will be of great significance in promoting the rapid development of the biomedical industry.

[0023] Mouse and rat models are one of the most important model animals in the biomedical field, and have made great contributions to the mechanism research and drug development of various human diseases. However, as scientists continue to deepen their understanding of diseases and refine their evaluation of drug effects, some shortcomings of mice and rats due to their distant evolutionary relationship with humans are becoming increasingly apparent, especially in terms of the nervous system, tissue anatomy, immune system, etc., which are quite different from humans and often cannot truly simulate the pathological process and symptom manifestations of human diseases. To make up for these shortcomings, miniature pigs and other animals often have advantages that are more similar to humans in terms of body size, tissue anatomy, physiology and biochemistry, and genome structure, and have been increasingly valued by the biomedical community. The human Ras gene is the most tumor-related proto-oncogene found in tumor patients so far. There are three main genes in its gene family that are related to human tumors: H-Ras, K-Ras, and N-Ras, and kras gene mutations exist in 30% of adenocarcinomas. Existing clinical data show that the mutation frequency of kras in lung cancer patients is as high as 17%-25%, and the mutation form is mainly point mutation, mainly concentrated in codons 12, 13, and 61, among which mutation in codon 12 is the most common, and the most common mutation form is mutation from G to D.

[0024] The Tet-On system has been widely used in the construction of K-Ras mutant mice due to its high efficiency, controllable, reversible, and low leakage expression. The introduction of an inducible gene expression system in pigs can precisely regulate the expression of exogenous genes in time and space, which is conducive to the in-depth analysis of gene function and the expansion of the application range of genetically modified pigs. However, there are few reports on the Tet-on system in pigs.

[0025] Example 1: Construction and activity verification of Tet-On transposon expression vector Based on PiggyBac, a transposon-induced expression plasmid was constructed, which included the flanking PiggyBac inverted terminal repeat sequence, three promoters and corresponding polyA sequences. The three promoters were TRE3GS (controlling the expression of its downstream multiple cloning site (MCS) element), CAG (controlling the expression of the transactivator protein (TetOn3g) and the reporter red fluorescent protein (mCherry)) and PGK (controlling the expression of the bidirectional drug screening gene), which were derived from PLVX-TetOne-Puro plasmid, PX458 plasmid and PGLE-U6-mCherry plasmid, respectively. The obtained plasmid PCR product was transformed into DH5α competent bacteria for amplification, and the single clone colony was picked and amplified again. After the plasmid was extracted and sent for sequencing. The screened target plasmid was named PB-CAG-Teton3g-T2A-mcherry-TRE3GS-MCS-Puro (PB-TMP-MCS). After sequencing and cutting with restriction endonuclease EcoRI, the in vitro synthesized HA-kras G12D The series (nucleotide sequence is shown in SEQ.ID.NO:1) was cloned into the MCS position and named PB-TMP-HA-kras after verification by resequencing. G12D , whose nucleotide sequence is shown in SEQ.ID.NO:2, and its vector construction strategy schematic diagram is shown in Figure 1 , 2 , 3, after the activity of the Tet-On vector was verified, the results were as follows Figure 4 , Figure 5 , Figure 6 As shown, the cells were further transfected into wild-type Diannan small-eared pig fetal fibroblast cell line.

[0026] Example 2: Construction and genotype analysis of K-Ras gene-inducible expression cloned pigs The PB-TMP-HA-kras successfully constructed in Example 1 G12DAfter the vector was transformed and the plasmid was extracted, it was co-transfected with the transposase at a ratio of 1:3 into the porcine fetal fibroblast cell line by electroporation. After 48 hours of maintenance and screening with 2μg / mL puromycin, extremely diluted single cell culture was performed. Single cell clones were formed after about 12 days of culture. A total of 43 single cell clones were picked and genomic DNA was extracted. After genotyping, 12 were determined to be positive monoclonal cell lines with inducible expression of the K-Ras gene. The 24# positive cell line identified as inducible expression of the K-Ras gene was used as the donor cell for somatic cell nuclear transplantation to construct cloned embryos with inducible expression of the K-Ras gene. The embryos were transplanted into estrus surrogate sows, and 9 porcine fetuses with inducible expression of the K-Ras gene were obtained at 33 days of gestation. Figure 7 A, one surrogate sow gave birth at 114 days of gestation to obtain four cloned pigs. The genomic DNA was extracted and the genotype identification showed that all four pigs (two survived) were cloned pigs with inducible expression of K-Ras gene. The success rate of constructing pigs or pig fetuses with K-Ras gene was 100%. Finally, two K-Ras gene inducible expression cloned pigs survived, and the survival rate of K-Ras gene edited pigs was 50%. The results are shown in Figure 8 .

[0027] Example 3: Phenotypic analysis of cloned pigs expressing inducible K-Ras gene For the cloned pigs with inducible expression of the K-Ras gene constructed in Example 2, the behavioral state, mental state, body weight and other phenotypes of the animals were observed and evaluated and recorded every week. A certain amount of tetracycline was fed in a timely manner, tetracycline was added to the daily feed, and the drug was administered once every 3 days, 30 mg / kg at a time. The tumor progression and pathological changes of the miniature pig model with inducible expression of the K-Ras gene were detected by imaging techniques such as CT, MRI, and PET-CT. Samples of different stages of the onset of the miniature pig tumor model, such as the early stage, progressive stage, and terminal stage, were collected, and the tumor staging and typing were comprehensively judged by HE staining, immunohistochemistry and other methods, and tumor markers were screened by liquid biopsy, and compared with the corresponding human malignant tumors to obtain a miniature pig tumor model with inducible expression of the K-Ras gene.

[0028] In summary, the present invention provides a method for constructing a K-Ras inducible expression miniature pig tumor model, which overcomes the technical problems of the existing model construction period, low efficiency, unclear phenotype, poor controllability of gene expression, etc., and can further realize the production of batch K-Ras gene inducible expression miniature pig tumor models through continuous cloning technology. After the obtained K-Ras gene inducible expression miniature pig model is induced by tetracycline, it shows the characteristics of tumor biology in physiology and biochemistry, cytology, histology, and imaging, and has important application value and prospects in the fields of human tumor biology, pathogenesis, and new drug research and development.

[0029] Finally, it should be noted that the above preferred embodiments are only used to illustrate the technical solutions of the present invention rather than to limit it. Although the present invention has been described in detail through the above preferred embodiments, those skilled in the art should understand that various changes can be made in form and details without departing from the scope defined by the claims of the present invention.

Claims

1. A method for constructing a miniature pig tumor model with inducible expression of K-Ras gene, characterized in that: The method comprises: (1) The transposon-induced expression plasmid was transformed into DH5α competent bacteria by PCR for amplification, and the PB-TMP-MCS target plasmid was screened; The transposon-induced expression plasmid includes flanking PiggyBac inverted terminal repeat sequences, three promoters and corresponding polyA sequences; (2) The PB-TMP-MCS target plasmid obtained in (1) was cut with restriction endonucleases, and the in vitro synthesized HA-kras series was cloned into the MCS position. After verification by sequencing, it was named PB-TMP-HA-kras. G12D ; The nucleotide sequence of the HA-kras is shown in SEQ.ID.NO:1; the PB-TMP-HA-kras G12D The nucleotide sequence is shown in SEQ.ID.NO:2; (3) The PB-TMP-HA-kras obtained in (2) G12D Co-transfected with transposase into porcine fetal fibroblast cell line by electroporation, and K-Ras gene editing-positive porcine fetal fibroblast cell line was obtained by single cell clone screening; (4) The K-Ras gene-edited positive porcine fetal fibroblast cell line obtained in (3) is used as a donor cell for somatic cell nuclear transplantation to construct a K-Ras gene-inducible expression cloned embryo, and the cloned embryo is further transplanted into the oviduct of a surrogate sow to obtain a K-Ras gene-inducible expression cloned pig after delivery.

2. The method according to claim 1, characterized in that The three promoters in (1) are TRE3GS, CAG and PGK; the TRE3GS is derived from the PLVX-TetOn-Puro plasmid; the CAG is derived from the PX458 plasmid; and the PGK is derived from the PGLE-U6-mCherry plasmid.

3. The method according to claim 1, characterized in that The restriction endonuclease in (2) is EcoRI enzyme.

4. The method according to claim 1, characterized in that: The transfection method in (3) is: liposome transfection and / or electroporation transfection; the donor cell in (4) is a K-Ras gene-edited single cell clone or cloned fetal fibroblast or cloned pig ear tissue fibroblast.

5. The method according to claim 4, characterized in that The transfection is electroporation transfection.

6. The method according to claim 1, characterized in that The method further comprises the following steps: (5) Identifying the K-Ras gene-inducible expression cloned pigs described in (4); the identification comprises performing histological, immunohistochemical, and omics analysis on the phenotype and organs of the K-Ras gene-inducible expression cloned pigs.

7. The method according to claim 1 or 6, characterized in that: The method further comprises the following steps: (6) The K-Ras gene inducible expression cloned pigs obtained in (4) were fed with tetracycline to maintain the stability of the model. The amount of tetracycline fed was 30 mg / kg, once every 3 days.

Citation Information

Patent Citations

  • Induced slow virus expression system and construction method and application thereof

    CN105331635A

  • Tetracycline slow virus inducible expression vector as well as building method and application thereof

    CN107523588A

  • Mutant KRAS-specific antibody and preparation method thereof

    CN110357965A

  • Transposon expression system tetracycline induction vector as well as preparation method and application thereof

    CN116396981A

  • Tumor mouse models using lentiviral vectors

    US20080292591A1